about
Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycleAn alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2Structure and function of the HOX A1 human homeobox gene cDNASphingomyelin synthase 1 suppresses ceramide production and apoptosis post-photodamageMicrotubule deacetylases, SirT2 and HDAC6, in the nervous systemGerm line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasmsDiagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays.Autoantibody approach for serum-based detection of head and neck cancer.Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.Paraneoplastic antigens as biomarkers for early diagnosis of ovarian cancerLoss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.Serum prognostic biomarkers in head and neck cancer patients.Stochastic cancer progression driven by non-clonal chromosome aberrations.Analysis of the expression of human tumor antigens in ovarian cancer tissuesImmunotheranostics: breaking tolerance in immunotherapy using tumor autoantigens identified on protein microarrays.Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.Non-traditional immunogens and their application to immunotherapy.Usage of cancer associated autoantibodies in the detection of diseaseCritical pathways in cellular senescence and immortalization revealed by gene expression profiling.Multianalyte tests for the early detection of cancer: speedbumps and barriers.Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.Genomic and proteomic biomarkers for cancer: a multitude of opportunities.Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.Risk perception and cancer worries in families at increased risk of familial breast/ovarian cancer.Diverse system stresses: common mechanisms of chromosome fragmentation.Expression profiling identifies three pathways altered in cellular immortalization: interferon, cell cycle, and cytoskeleton.Assessing the functional bias of commercial microarrays using the onto-compare database.Functional characterization of the interacting domains of the positive coactivator PC4 with the transcription factor AP-2alpha.PA-1, a human cell model for multistage carcinogenesis: oncogenes and other factors.PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation.Analysis of the virogenes related to the rhesus monkey endogenous type C retrovirus in monkeys and apes.Breast cancer risk and germline genomic profiling of women with neurofibromatosis type 1 who developed breast cancer.Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2'-deoxycytidine sensitizes human breast cancer cells to adriamycin.Isolation and characterization of a breast progenitor epithelial cell line with robust DNA damage responses.Stat1 expression is not sufficient to regulate the interferon signaling pathway in cellular immortalization.Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.Molecular phenotyping of head and neck cancer.drp, a novel protein expressed at high cell density but not during growth arrest.Aflatoxin B1-induced immortalization of cultured skin fibroblasts from a patient with Li-Fraumeni syndrome.The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.
P50
Q24299947-488C0F02-EFA8-4A48-B84A-A25871E3B1B2Q24308857-EE2DEDF3-C04B-48AC-BDD9-DE80272084B8Q24319805-747EEF24-2A48-40D3-8D37-63D6FFCE1E14Q24657900-45F919E7-2032-463B-9911-56ADCBAB90BAQ28510189-A8D187F3-7A2D-48D9-8789-DE45DDC874F3Q29618586-D25CE3B4-519B-4ED7-8C41-0BA15D2EB865Q33232102-E119CA7B-7E1C-4079-ABCD-27D83414A84EQ33305783-24839643-A2E4-4EFC-8D87-479F022B0CA0Q33772896-27048344-8225-4F44-8BF4-3F308D11E72BQ33812271-9A044058-25EC-4996-9A6B-660ABE87D867Q33889210-4031DF45-BFF2-4B5D-8301-6B281C5B76BAQ34032646-11B6E8FF-D90D-44DB-9254-4A61C3EDAAB7Q34524376-AA2ED623-9E04-4F2F-B8C3-4A2D42F15C26Q35930779-723298A2-0F21-4E11-8731-3BC9938A8B6BQ36490440-9F7AEF72-46AE-4BF1-AEF7-0F70FD4F1DBCQ36517359-68CA3F1C-E8B1-444E-BCF6-449EB00FCC92Q37070425-52AC6DF4-1A83-40F6-806E-5BD8828FDB0AQ37217734-6CE648DD-D0F3-48C9-85BC-BB4CFD7E6C12Q37246647-B24C1549-8B23-4E73-A857-DEA21055B153Q37280916-FBBF5E63-389B-4D9D-A5D4-54701DE7B126Q37285033-9CC72885-7838-439C-8E2F-300DEDD91715Q37363928-B0FD4BA3-1A51-428B-A709-FD398831A403Q37582080-CEA59232-9D31-47BA-B6FC-6EC2DA29CBCBQ37626759-C8243E25-26BA-44C2-A089-8065DAF4C7EAQ38347487-2B2AC4A7-68B0-4379-8D1A-D2833CDA4D5BQ38517737-8347A902-D09D-4F26-B4CB-DF4B58D66A20Q38522857-F75137B3-F760-41FB-8920-B24C159E6C3CQ39388383-EB1A7496-4A50-4381-8C73-F7D3EA3E810CQ39532060-17B42587-FF58-4312-957F-16D837F6DA46Q39727130-A0F979E0-EEA3-4081-9F88-C6A4E812E9A0Q39813531-1BE1A210-E5AB-4494-B1BD-77B840588E0DQ40048246-8B66760E-7E51-4495-A421-914564D79CF9Q40174195-AC48714D-5101-4CF5-8F67-E0B4AEEAA9A3Q40303961-9EB855E9-BDC0-4514-ADE6-33968ADE3826Q40327022-3C1EE09A-BBC6-4EA2-8EC7-C09203088E25Q40345570-404C23A3-704E-45B4-AFF8-C45E80EEF442Q40543933-69AE3276-82F3-4B1D-AEE2-5656D3236AFEQ41033923-1A47A667-5EAF-44E1-9A48-DE6363315B84Q41390877-9053F286-A26C-48B5-BED7-EAE394316F2BQ41506143-36C83CBA-ED33-4785-9C84-2D6583031CB2
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
M A Tainsky
@ast
M A Tainsky
@en
M A Tainsky
@es
M A Tainsky
@nl
type
label
M A Tainsky
@ast
M A Tainsky
@en
M A Tainsky
@es
M A Tainsky
@nl
prefLabel
M A Tainsky
@ast
M A Tainsky
@en
M A Tainsky
@es
M A Tainsky
@nl
P31
P496
0000-0002-0261-831X